The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−

apoe gene diet

Apoe gene diet

The GLP-1RAs liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients.

In ApoE −/− mice and LDLr −/− mice, liraglutide and semaglutide treatment significantly attenuated plaque lesion development, in part independently of body weight and cholesterol lowering.

Semaglutide decreased levels of plasma markers of systemic inflammation in an acute inflammation model (lipopolysaccharide), and transcriptomic analysis of aortic atherosclerotic tissue revealed that multiple inflammatory pathways were down-regulated by semaglutide.

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients. The mode of action is suggested to occur through modified atherosclerotic progression. In this study, both of the compounds significantly attenuated plaque lesion development in apolipoprotein E-deficient (ApoE −/− ) mice and low-density lipoprotein receptor-deficient (LDLr −/− ) mice. This attenuation was partly independent of weight and cholesterol lowering. In aortic tissue, exposure to a Western diet alters expression of genes in pathways relevant to the pathogenesis of atherosclerosis, including leukocyte recruitment, leukocyte rolling, adhesion/extravasation, cholesterol metabolism, lipid-mediated signaling, extracellular matrix protein turnover, and plaque hemorrhage. Treatment with semaglutide significantly reversed these changes. These data suggest GLP-1RAs affect atherosclerosis through an anti-inflammatory mechanism.

Visual Abstract

  1. Download high-res image (932KB)
  2. Download full-size image

Previous article in issue
Next article in issue

Leave a Reply

Your email address will not be published. Required fields are marked *